首页> 美国卫生研究院文献>other >Novel somatic and germline mutations in intracranial germ cell tumors
【2h】

Novel somatic and germline mutations in intracranial germ cell tumors

机译:颅内生殖细胞肿瘤中的新型体细胞和种系突变

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Intracranial germ cell tumors (IGCTs) are a group of rare heterogeneous brain tumors which are clinically and histologically similar to the more common gonadal GCTs. IGCTs show great variation in their geographic and gender distribution, histological composition and treatment outcomes. The incidence of IGCTs is historically 5–8 fold greater in Japan and other East Asian countries than in Western countries with peak incidence near the time of puberty. About half of the tumors are located in the pineal region. The male-to-female incidence ratio is approximately 3–4:1 overall but even higher for tumors located in the pineal region. Due to the scarcity of tumor specimens available for research, little is currently known about this rare disease. Here we report the analysis of 62 cases by next generation sequencing, SNP array and expression array. We find the KIT/RAS signaling pathway frequently mutated in over 50% of IGCTs including novel recurrent somatic mutations in KIT, its downstream mediators KRAS and NRAS, and its negative regulator CBL. Novel somatic alterations in the AKT/mTOR pathway included copy number gain of the AKT1 locus at 14q32.33 in 19% of patients, with corresponding upregulation of AKT1 expression. We identified loss-of-function mutations in BCORL1, a transcriptional corepressor and tumor suppressor. We report significant enrichment of novel and rare germline variants in JMJD1C, a histone demethylase and coactivator of the androgen receptor, among Japanese IGCT patients. This study establishes a molecular foundation for understanding the biology of IGCTs and suggests potentially promising therapeutic strategies focusing on the inhibition of KIT/RAS activation and the AKT1/mTOR pathway.
机译:颅内生殖细胞肿瘤(IGCT)是一组罕见的异质性脑肿瘤,在临床和组织学上与更常见的性腺GCT相似。 IGCT显示出其地理和性别分布,组织学组成和治疗结果的巨大差异。从历史上看,日本和其他东亚国家中IGCT的发生率是西方国家中的5-8倍,而青春期时发生率达到峰值。 大约一半的肿瘤位于松果体区域。总体而言,男女发病率大约为3–4:1,但对于位于松果体区域 的肿瘤,其发病率甚至更高。由于缺乏可用于研究的肿瘤标本,目前对这种罕见疾病知之甚少。在这里,我们报告通过下一代测序,SNP阵列和表达阵列对62例病例的分析。我们发现,超过50%的IGCT中经常发生KIT / RAS信号通路突变,包括KIT中的新型复发性体细胞突变,其下游介质KRAS和NRAS以及其负调控因子CBL。 AKT / mTOR途径的新型体细胞改变包括19%的患者在14q32.33处AKT1基因座的拷贝数增加,并相应地上调AKT1表达。我们确定了BCORL1,一个转录共抑制物和肿瘤抑制物的功能丧失突变。我们报道了日本IGCT患者中JMJD1C,组蛋白脱甲基酶和雄激素受体的共激活因子JMJD1C中新的和稀有种系变体的大量富集。这项研究为理解IGCT的生物学奠定了分子基础,并提出了潜在的有前途的治疗策略,重点在于抑制KIT / RAS激活和AKT1 / mTOR途径。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号